A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of the
combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory
lymphomas.